More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody, which suggests the drug boasts similar safety and efficacy in non ...
Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results